A detailed history of Marshall Wace, LLP transactions in Guardant Health, Inc. stock. As of the latest transaction made, Marshall Wace, LLP holds 119,878 shares of GH stock, worth $3.45 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
119,878
Holding current value
$3.45 Million
% of portfolio
0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$17.13 - $26.91 $2.05 Million - $3.23 Million
119,878 New
119,878 $2.47 Million
Q2 2023

Aug 14, 2023

BUY
$20.94 - $38.01 $6.97 Million - $12.6 Million
332,733 Added 1615.21%
353,333 $12.6 Million
Q1 2023

May 15, 2023

BUY
$22.92 - $33.76 $288,929 - $425,578
12,606 Added 157.69%
20,600 $482,000
Q4 2022

Feb 14, 2023

BUY
$25.44 - $59.78 $203,367 - $477,881
7,994 New
7,994 $217,000
Q1 2022

May 16, 2022

SELL
$48.25 - $100.49 $190,780 - $397,337
-3,954 Closed
0 $0
Q4 2021

Feb 14, 2022

SELL
$88.71 - $120.43 $29.5 Million - $40 Million
-332,250 Reduced 98.82%
3,954 $396,000
Q2 2021

Aug 13, 2021

BUY
$109.77 - $165.68 $31.7 Million - $47.9 Million
288,913 Added 610.93%
336,204 $41.8 Million
Q1 2021

May 17, 2021

SELL
$127.04 - $179.1 $114 Million - $161 Million
-899,591 Reduced 95.01%
47,291 $7.22 Million
Q4 2020

Feb 16, 2021

BUY
$99.96 - $135.93 $1.53 Million - $2.08 Million
15,300 Added 1.64%
946,882 $122 Million
Q3 2020

Nov 16, 2020

SELL
$80.32 - $111.8 $47.1 Million - $65.6 Million
-586,500 Reduced 38.63%
931,582 $104 Million
Q2 2020

Aug 13, 2020

BUY
$60.49 - $97.5 $50.4 Million - $81.2 Million
833,174 Added 121.65%
1,518,082 $123 Million
Q1 2020

May 15, 2020

BUY
$59.04 - $88.81 $40.4 Million - $60.8 Million
684,908 New
684,908 $47.7 Million

Others Institutions Holding GH

About Guardant Health, Inc.


  • Ticker GH
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 102,220,000
  • Market Cap $2.94B
  • Description
  • Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a cl...
More about GH
Track This Portfolio

Track Marshall Wace, LLP Portfolio

Follow Marshall Wace, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Marshall Wace, LLP with notifications on news.